MedTrace Logo

BPC 157 for Acute Hamstring Muscle Strain Repair

NCT07437547 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-02-27

No results posted yet for this study

Summary

This randomized, double-blind, placebo-controlled Phase 2 study evaluates whether pentadecapeptide BPC 157 (BPC-157), an investigational peptide, can speed structural healing and functional recovery after an acute grade II hamstring muscle strain. Participants will receive BPC 157 or placebo for 14 days in addition to a standardized rehabilitation program. The co-primary endpoints are time to return to unrestricted sport and change in MRI-assessed injury volume at Day 14.

Conditions

  • Hamstring Muscle Strain
  • Skeletal Muscle Injury

Interventions

DRUG

Pentadecapeptide BPC 157

subcutaneous injection (administered by trained study staff). Schedule: once daily for 14 days.

DRUG

Placebo

subcutaneous injection (administered by trained study staff). Schedule: once daily for 14 days.

Sponsors & Collaborators

  • Hudson Biotech

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-02
Primary Completion
2027-02-14
Completion
2028-02-17

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07437547 on ClinicalTrials.gov